{"id":"ven-combined-with-azacitidine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Azacitidine is a hypomethylating agent that inhibits DNA methyltransferase, leading to increased expression of tumor suppressor genes. VEN, a histone deacetylase inhibitor, further promotes cell differentiation and apoptosis by modifying chromatin structure.","oneSentence":"VEN combined with azacitidine works by inhibiting DNA methyltransferase and histone deacetylase, leading to epigenetic modifications that promote cell differentiation and apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:50.189Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT06852222","phase":"PHASE3","title":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-06-04","conditions":"Leukemia, Myeloid, Acute","enrollment":600},{"nctId":"NCT07007312","phase":"PHASE3","title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2025-09-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":1300},{"nctId":"NCT05453903","phase":"PHASE1","title":"A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":196},{"nctId":"NCT06456463","phase":"PHASE2","title":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2025-01-14","conditions":"Acute Myeloid Leukemia","enrollment":83},{"nctId":"NCT05768711","phase":"PHASE2","title":"Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2023-10-04","conditions":"Chronic Myeloid Leukemia","enrollment":44},{"nctId":"NCT07304011","phase":"PHASE2","title":"Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-12-17","conditions":"Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT07425782","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine for Consolidation Therapy in AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-02-01","conditions":"Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax","enrollment":216},{"nctId":"NCT07177079","phase":"PHASE1","title":"High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)","status":"NOT_YET_RECRUITING","sponsor":"Kittika Poonsombudlert","startDate":"2026-05-31","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT07318662","phase":"","title":"Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2020-01-01","conditions":"MDS, CMML","enrollment":224},{"nctId":"NCT06030089","phase":"NA","title":"Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2024-02-26","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT05566054","phase":"PHASE2","title":"Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-03-01","conditions":"Acute Monocytic Leukemia, Newly Diagnosed","enrollment":92},{"nctId":"NCT04609826","phase":"PHASE1","title":"A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-11-26","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia","enrollment":153},{"nctId":"NCT04512105","phase":"PHASE1","title":"Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2020-12-02","conditions":"Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult","enrollment":6},{"nctId":"NCT07159620","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-01","conditions":"Adult T-cell Leukemia/Lymphoma","enrollment":27},{"nctId":"NCT06429098","phase":"PHASE2","title":"Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-01-01","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT07047183","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes","status":"RECRUITING","sponsor":"Yehui Tan","startDate":"2025-07-01","conditions":"Myelodysplastic Neoplasms, Transplantation","enrollment":46},{"nctId":"NCT06158100","phase":"PHASE1","title":"Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)","status":"SUSPENDED","sponsor":"Antonio M Jimenez Jimenez","startDate":"2024-12-04","conditions":"Acute Myeloid Leukemia","enrollment":25},{"nctId":"NCT07007949","phase":"PHASE2","title":"a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-06-01","conditions":"Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib","enrollment":42},{"nctId":"NCT06390306","phase":"","title":"The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-07-01","conditions":"Chronic Myeloid Leukemia","enrollment":30},{"nctId":"NCT06066242","phase":"NA","title":"Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-10-01","conditions":"Acute Myeloid Leukemia","enrollment":90},{"nctId":"NCT06696183","phase":"PHASE2","title":"Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2025-04-25","conditions":"AML - Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT06634394","phase":"PHASE1","title":"APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML","status":"RECRUITING","sponsor":"Aptevo Therapeutics","startDate":"2024-10-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":39},{"nctId":"NCT06841952","phase":"NA","title":"Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-02-15","conditions":"AML, Adult","enrollment":158},{"nctId":"NCT04372433","phase":"PHASE1","title":"IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML","status":"COMPLETED","sponsor":"Immune-Onc Therapeutics","startDate":"2020-09-14","conditions":"AML With Monocytic Differentiation, CMML","enrollment":67},{"nctId":"NCT06810791","phase":"PHASE3","title":"HVA vs IA/DA or VA in the Treatment of ND HR-AML","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-01-01","conditions":"Newly Diagnosed Acute Myeloid Leukemia With High Risk","enrollment":876},{"nctId":"NCT04476199","phase":"PHASE2","title":"Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","startDate":"2019-12-09","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT05833438","phase":"PHASE2","title":"Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy","status":"RECRUITING","sponsor":"University of Leipzig","startDate":"2023-05-17","conditions":"Acute Myeloid Leukemia (AML)","enrollment":45},{"nctId":"NCT06612944","phase":"PHASE2","title":"Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-11-12","conditions":"Myelodysplastic Syndromes, Adult","enrollment":40},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT06084819","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2023-08-01","conditions":"Relapsed/Refractory Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT06073730","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Kunming Medical University","startDate":"2023-11-01","conditions":"Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia","enrollment":154},{"nctId":"NCT05264883","phase":"PHASE3","title":"Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-03-01","conditions":"Acute Myeloid Leukemia","enrollment":170},{"nctId":"NCT05823714","phase":"PHASE2","title":"Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-01-20","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":70},{"nctId":"NCT05809167","phase":"PHASE2","title":"Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-01-20","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia","enrollment":55},{"nctId":"NCT05448599","phase":"PHASE1, PHASE2","title":"A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-07-08","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT05584761","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-03-01","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-2, Secondary Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT05457361","phase":"PHASE3","title":"VAH Versus VA for Salvage Therapy of R/R-AML","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-03-01","conditions":"Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine","enrollment":162},{"nctId":"NCT05456048","phase":"","title":"Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-12-03","conditions":"Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Gene Abnormality","enrollment":231},{"nctId":"NCT05431257","phase":"PHASE2","title":"Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2022-05-24","conditions":"Acute Myeloid Leukemia","enrollment":117},{"nctId":"NCT04904237","phase":"PHASE2","title":"Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-01-01","conditions":"Refractory Acute Myeloid Leukemia","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VEN combined with azacitidine","genericName":"VEN combined with azacitidine","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VEN combined with azacitidine works by inhibiting DNA methyltransferase and histone deacetylase, leading to epigenetic modifications that promote cell differentiation and apoptosis in cancer cells. Used for Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}